Biotechnology News and Research

RSS

Four Geisinger Health System researchers receive $25M grant to initiate ClinGen Project

Four Geisinger Health System researchers have taken center stage in the national arena of genomics thanks to new funding from the National Human Genome Research Institute (NHGRI), an arm of the U.S. National Institutes of Health (NIH).

27 Sep 2013

Allergan Licenses Rights To Medytox Candidates, In Up-To-$362M Deal

...

26 Sep 2013

Biosearch Technologies Acquires Majority Stake In Lightspeed Genomics

...

26 Sep 2013

VolitionRx enters into distribution agreement with Active Motif for NuQ product line

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today entered into an agreement with Active Motif, a leading provider of kits and reagents to enable epigenetics research.

26 Sep 2013

Results of NovaRx's Lucanix Phase III trial in non-small cell lung cancer to be presented at ESMO 2013

NovaRx Corporation announced that the detailed results from the randomized Phase III trial of Lucanix (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer will be presented at the European Society for Medical Oncology 2013 annual meeting in Amsterdam.

26 Sep 2013

Three research groups awarded NIH grants to develop framework for evaluating genetic variants

Three grants totaling more than $25 million over four years will help three research groups to develop authoritative information on the millions of genomic variants relevant to human disease and the hundreds that are expected to be useful for clinical practice. The awards are from the National Institutes of Health.

26 Sep 2013

Ten health care innovations could save lives of mothers and children

Ten health care innovations, if brought to scale immediately in low-resource countries, could have the potential to save the lives of some 1.2 million mothers and children in 2015.

26 Sep 2013

Federal Data Shows R&D Spending Slide

...

25 Sep 2013

Amgen Plans R&D Center In China

...

25 Sep 2013

Global Genomics Group Enlists Illumina For Cardiovascular Disease Study

...

From Illumina, Inc. 25 Sep 2013

NCI Re-Ups Biomarker Strategies’ SBIR Award For Melanoma Cdx

BioMarker Strategies received a $1.5 million SBIR award to develop a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for patients with melanoma. This award was preceded by an NCI award of $200,000 almost two years ago in September 2011.

25 Sep 2013

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

25 Sep 2013

UCSF inaugurates new endowment of PhD education programs in basic sciences

Sequoia Capital Chairman Sir Michael Moritz, KBE, and his wife, Harriet Heyman, in collaboration with UC San Francisco, have kicked off a new endowment with a $60 million contribution to ensure the future of PhD education programs in the basic sciences.

25 Sep 2013

inVentiv Health Clinical releases new tool to connect physicians participating in late-stage research

inVentiv Health Clinical, a leading global supplier of drug development services, today announced the launch of an innovative, web-based network to efficiently connect physicians interested in participating in late-stage research to appropriate clinical trials.

24 Sep 2013

Quartette tablets now available in U.S. for prevention of pregnancy

Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets are now available via prescription in the U.S. for the prevention of pregnancy.

24 Sep 2013

Pancreatic Cancer Imaging Agent Earns Mabvax $1.75M SBIR Award

...

24 Sep 2013

NCI Funds Development Of Chrysalis’ Brain Tissue Damage Treatment

The National Cancer Institute awarded Chrysalis BioTherapeutics a $1.5 million contract to continue development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. The project is a collaboration between Chrysalis, Baylor College of Medicine, and the University of Texas Medical Branch (UTMB).

24 Sep 2013